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hypertension, and insulin resistance, suggesting that systemic factors could
also play a role in the genesis of OA joint damage.
A number of deﬁned metabolic diseases may also lead to non-inﬂammatory
arthropathy with radiographic features predominantly of OA. The principal
conditions that predispose to secondary OA are ochronosis, wilson’s dis-
ease, acromegaly and hereditary hemochromatosis (HH). The most common
form of HH is an autosomal recessive iron overload disorder associated
with mutation of the HFE gene. Affected individuals may present with a
severe arthropathy mimicking OA, typically involving the second and third
metacarpophalangeal joints, which may seriously affect quality of life.
Other metabolic diseases, like chronic hypomagnesaemia or primary hyper-
parathyroidism may lead to deposition of calcium pyrophosphate crystals
within cartilage. These deposits, named chondrocalcinosis when identi-
ﬁed by X-Rays, are associated with OA, which may present with more
inﬂammatory symptoms, an atypical distribution and prominent cyst and
osteophyte formation on radiographs.
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Despite all the advances in bone and cartilage biology, particularly in
the recent bone and joint decade, there are still some deﬁciencies in our
understanding of the pathogenesis of osteoarthritis (OA), as well as our
ability to diagnose and treat OA. Nanomedicine is expected to improve
the ADL of patients with OA through the advances in the technology for
diagnosis and treatment.
(1) Oxidative DNA damage contributes to aging and degeneration of ar-
ticular cartilage. During the development of OA, mechanical and chemical
stresses on articular cartilage change the stable cellular activities of chon-
drocytes and produce excess amounts of reactive oxygen species (ROS) as
well as proinﬂammatory cytokines and chemokines. Studies have provided
ample conﬁrmation of the accumulation of ROS and the chondrocyte aging
in degenerated articular cartilage.
Our recent study revealed the potential involvement of accumulation of 8-
Oxoguanine, an oxidized form of guanine, and impairment of mitochondrial
DNA repair enzymes in the pathogenesis of OA. 8-Oxoguanine is produced
by ROS in large amounts in both DNA and nucleotide pools and is a major
causative lesion for mutagenesis by ROS in a variety of diseases.
We observed the increased level of 8-Oxoguanine and decreased level of
Ogg1 in osteoarthritic chondrocytes of degenerated cartilage in comparison
with chondrocytes of intact cartilage in animal models of OA and in patients
with OA, suggesting the involvement of the accumulation of 8-Oxoguanine
in articular chondrocytes and down-regulation of its repair enzyme Ogg1
in the degeneration of articular cartilage in OA. We found that over-
expression of mitochondria-targeted human hOgg1 in human osteoarthritis
chondrocytes prevents oxidant-induced mitochondrial dysfunction, OA re-
lating catabolic stress-induced caspase-9 activation and apoptosis in vitro.
Furthermore, hOgg1 silencing using siRNA reduced chondrocyte activity
and augments apoptosis in human ostearthritic chondrocytes.
(2) Application of nanotechnology to chondroprotection. In the previous
studies, we have focused on nanocarbon particle, fullerene (C60), which
acts a strong free radical scavenger, as an anti-oxidative agent, to prevent
the degeneration of articular cartilage in OA. We have demonstrated that
water-soluble fullerene has a potential as a protective agent against the
catabolic stress-induced degeneration of articular cartilage both in vitro
andin vivo OA models.
In this paper, we demonstrate that mitochondrial 8-Oxoguanine DNA
glycosylase regulates the cellular function and survival of osteoarthritic
chondrocytes in response to catabolic stresses in OA. In addition, we show
that C60 fullerene may inﬂuence the expressions of mitochondrial DNA
repair enzymes and their functions in osteoarthritic chondrocytes, suggest-
ing that C60 fullerene has a therapeutic potential, as a nanomedicine, to
protect against the degeneration of articular cartilage in OA. We would like
to conclude the pathomechanism of OA in terms of the chondrocyte ability
and function in response to oxidative stress by augmenting DNA repair.
(3) Application of bone and cartilage imaging. Magnetic resonance imag-
ing (MRI) is now thought an effective tool in the image diagnosis of OA.
However, spatial resolution of MRI is limited to a span of one to several
millimeters. While conventional X-ray imaging system has been used in
the image diagnosis of various diseases, cartilage cannot be depicted with
them. There has been a strong call for an X-ray imaging technology that can
depict cartilage. More recently, Kido K. et al. demonstrated a novel X-ray
imaging system which it would be easier to detect the onset of a disease,
to diagnose the stage of the disease, and to monitor the effect of treatment
for bone and cartilage diseases. We also show their excellent technology of
image diagnosis, an X-ray Talbot-Lau interferometry, for degenerated bone
and cartilage.
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Regenerative Medicine aims to reconstruct or regenerate damaged or lost
tissue function due to trauma, disease or congenital defects, ideally without
tissue scarring. As articular cartilage does not heal, restoring damaged joint
surfaces has been a typical example where regmed approaches have been
explored extensively for over 15 years.
With the adoption of a new regulatory framework for Advanced Therapy
Medicinal Products (ATMP) at the end of 2007, also for cellular and/or
combinations products, the path of product development has become more
clear. Characterization of the cellular product by viability, identity, potency
and purity together with appropriate preclinical and toxicity studies, and
validation of a good manufacturing process (GMP) are all part of and critical
in this track of development. So far, one autologous cartilage cell product
has obtained central regulatory approval for the repair of symptomatic
articular cartilage defects in the knee. The data of the short and long term
follow up conﬁrm structural superiority over microfracture, considered
the standard of care. Clinical superiority over microfracture is particularly
striking for patients with a relatively recent medical history (less then 5
years).
Additional explorative trials for cartilage repair using variations on autolo-
gous cell based approaches, including the use of collagen membranes, have
provided valuable information about study design, mechanisms of repair
and clinical outcome and have revealed that further improvements could
be achieved. Besides expanded autologous articular chondrocytes, the use
of allogenic progenitor cell populations are now considered as an important
goal.
Some promising results have been reported in animal studies using pro-
genitor and mesenchymal cell populations (MSC) in post-traumatic models
of osteoarthritis (OA). However, before being able to evaluate the role of
cellular therapies in OA, more detailed information is needed on many
aspects including mechanisms of action, the fate of the cells, choice of cell
type and tissue origin, and culture parameters. Indeed, the mechanisms by
which MSC may contribute to tissue repair in OA are diverse and include
trophic effects, anti-inﬂammatory effects and direct tissue repair through
engraftment. The use of biomarkers to identify mechanistic events and
patients responding to treatment is an important step forward for these
more sophisticated regenerative approaches in OA.
In conclusion, there is hope for regenerative medicine, in particular in joint
an skeletal applications.
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Purpose: Chronic pain is a hallmark of osteoarthritis (OA), yet little is
known about its properties and representation in the brain. Previous
studies from our group in other pain states have demonstrated distinct
global and local brain morphological changes. The current investigations in
patients with OA were undertaken to compare this condition and ascertain
its speciﬁcity in comparison to other clinical chronic pain conditions.
Methods: Psychophysical measurements to examine the magnitude and
temporal properties of pain perception were coupled with fMRI to evaluate
brain activity in healthy controls and OA patients and relate brain activity to
clinical parameters of the disease. Voxel-based morphometry was utilized
to determine gray matter changes in OA and compared to other chronic
